3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Keratosis, Actinic
5
Uterine Cervical Neoplasms
3
Uterine Cervical Dysplasia
2
Papillomavirus Infections
2
Melanoma
2
Hemangioma, Capillary
2
Breast Neoplasms
2
Vulvar Neoplasms
1
Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)
1
Virus Diseases
1
Vaginal Neoplasms
1
Urinary Bladder Neoplasms
1
Skin Neoplasms
1
Sexually Transmitted Diseases
1
Precancerous Conditions
1
Pigmentation Disorders
1
Ovarian Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hemangioma
1
HPV
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Condylomata Acuminata
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Basal Cell
1
Carcinoma in Situ
1
Interventions
Oxaliplatin
67
Capecitabine
60
Fluorouracil
58
Bevacizumab
54
Gemcitabine
51
Paclitaxel
50
Leucovorin
50
Irinotecan
40
Docetaxel
39
Carboplatin
39
Cisplatin
38
pembrolizumab
37
Nivolumab
37
Cetuximab
35
Sunitinib
25
Trastuzumab
24
Radiosurgery
24
Radiotherapy
21
Doxorubicin
21
Cyclophosphamide
21
Panitumumab
20
Drug Therapy
19
Pemetrexed
18
Everolimus
18
Sorafenib
17
Interleukin-2
16
Fulvestrant
16
Albumin-Bound Paclitaxel
16
atezolizumab
15
Erlotinib Hydrochloride
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasm Metastasis
×
Imiquimod
×
Clear all
NCT06686043
2024-11-13
HPV-VIM
Baylor College of Medicine
Phase 2
Recruiting
85 enrolled